Berkshire Hathaway Purchases Shares of Amgen
1 report, 1 independent
Updated Sep 22
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Berkshire Hathaway disclosed a large share purchase of Amgen on September 22, 2026. On the same day, Amgen shares gained more than 3%, a rise attributed by reports to positive Phase 3 trial results for dazodalibep, which targets moderate-to-severe Sjögren's disease in adults.
From cnbc.com
Why it matters
The purchase by a major conglomerate like Berkshire Hathaway reflects institutional interest in the biopharmaceutical sector. This type of large-scale investment can signal confidence in the long-term financial health and growth prospects of Amgen.
From cnbc.com
Who's involved
- Berkshire HathawayAmerican multinational conglomerate holding company that purchased shares
- AmgenAmerican multinational biopharmaceutical company whose shares were purchased
Keep exploring
The entities involved
-
Berkshire Hathaway
American multinational conglomerate holding company
-
Amgen
American multinational biopharmaceutical company
Related events
- Berkshire Hathaway is aggressively buying Google while also trimming its stake in Ally Financial, leveraging its long-term ownership of American Express.
- Berkshire Hathaway made stock purchases while NBER released data tracking U.S. economic expansions.
- Amgen Inc. trades on the NASDAQ stock exchange.
- Berkshire Hathaway took a stake in IBM, and SpaceX shares began trading on Nasdaq.
- Cantor Fitzgerald and other analyst firms issued ratings on Amgen stock, which is listed on the Nasdaq exchange.